Profil
Tyson Kim currently works at Syntekabio, Inc, as Chief Executive Officer from 2015 and Radexel Co. Ltd., as Chief Executive Officer.
Postes actifs de Tyson Kim
| Sociétés | Poste | Début |
|---|---|---|
| SYNTEKABIO, INC. | Directeur Général | 01/01/2015 |
Radexel Co. Ltd.
 Radexel Co. Ltd. Medical SpecialtiesHealth Technology Radexel Co. Ltd. is a medical technology company based in Seoul, KR. The company was founded in 2018 by CEO Tyson Kim on the basis of Seoul Asan Medical Center development technology. Radexel is developing a radiation therapy device that treats cancer precisely with the world's first developed magnetic-radiation fusion technology and AI treatment plan. The device reduces side effects of normal tissue adjacent to cancer and improves treatment effect. It is also low-cost and compact, and can be installed in the same space as the existing radiation therapy device. | Directeur Général | - |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| SYNTEKABIO, INC. | Technology Services |
| Entreprise privées | 1 |
|---|---|
Radexel Co. Ltd.
Radexel Co. Ltd. Medical SpecialtiesHealth Technology Radexel Co. Ltd. is a medical technology company based in Seoul, KR. The company was founded in 2018 by CEO Tyson Kim on the basis of Seoul Asan Medical Center development technology. Radexel is developing a radiation therapy device that treats cancer precisely with the world's first developed magnetic-radiation fusion technology and AI treatment plan. The device reduces side effects of normal tissue adjacent to cancer and improves treatment effect. It is also low-cost and compact, and can be installed in the same space as the existing radiation therapy device. | Health Technology |
